27565913|t|Serum mass profile signature as a biomarker of early lung cancer
27565913|a|Circulating molecular biomarkers of lung cancer may allow the pre-selection of candidates for computed tomography screening or increase its efficacy. We aimed to identify features of serum mass profile distinguishing individuals with early lung cancer from healthy participants of the lung cancer screening program. Blood samples were collected during a low-dose computed tomography (LD-CT) screening program performed by one institution (Medical University of Gdansk, Poland). MALDI-ToF mass spectrometry was used to characterize the low- molecular-weight (1000-14,000Da) serum fraction. The analysis comprised 95 patients with early stage lung cancer (including 30 screen-detected cases) and a matched group of 285 healthy controls. The cases were split into two independent cohorts (discovery and validation), analyzed separately 6 months apart. Several molecular components of serum (putatively components of endogenous peptidome) discriminating patients with early lung cancer from controls were identified in a discovery cohort. This allowed building an effective cancer classifier as a model tuned to maximize negative predictive value, with an area under the curve (AUC) of 0.88, a negative predictive value of 100%, and a positive predictive value of 48%. However, the classifier performed worse in a validation cohort including independent sample sets (AUC 0.73, NPV 88% and PPV 30%). We developed a serum mass profile -based signature identifying patients with early lung cancer. Although this marker has insufficient value as a stand-alone preselecting tool for LD-CT screening, its potential clinical usefulness in evaluation of indeterminate pulmonary nodules deserves further investigation.
27565913	0	18	Serum mass profile	T059	C1446041
27565913	19	28	signature	T169	C1704864
27565913	34	43	biomarker	T201	C0005516
27565913	47	52	early	T079	C2363430
27565913	53	64	lung cancer	T191	C0242379
27565913	65	76	Circulating	T169	C0175630
27565913	77	97	molecular biomarkers	T201	C0005516
27565913	101	112	lung cancer	T191	C0242379
27565913	127	140	pre-selection	T062	C0242481
27565913	159	178	computed tomography	T060	C0040405
27565913	179	188	screening	T058	C0220908
27565913	205	213	efficacy	T080	C1280519
27565913	248	266	serum mass profile	T059	C1446041
27565913	282	293	individuals	T098	C0237401
27565913	299	304	early	T079	C2363430
27565913	305	316	lung cancer	T191	C0242379
27565913	322	342	healthy participants	T098	C1708335
27565913	350	379	lung cancer screening program	T061	C0281477
27565913	381	394	Blood samples	T031	C0178913
27565913	419	427	low-dose	T081	C0445550
27565913	428	447	computed tomography	T060	C0040405
27565913	449	454	LD-CT	T060	C0040405
27565913	456	473	screening program	T058	C0220908
27565913	491	502	institution	T093	C2607850
27565913	504	532	Medical University of Gdansk	T073,T093	C0020028
27565913	534	540	Poland	T083	C0032356
27565913	543	570	MALDI-ToF mass spectrometry	T062	C1518101
27565913	605	621	molecular-weight	T081	C0026385
27565913	638	643	serum	T031	C0229671
27565913	644	652	fraction	T081	C1264633
27565913	658	666	analysis	T062	C0936012
27565913	680	688	patients	T101	C0030705
27565913	694	705	early stage	T079	C2363430
27565913	706	717	lung cancer	T191	C0242379
27565913	782	798	healthy controls	T080	C2986479
27565913	830	841	independent	T078	C0085862
27565913	842	849	cohorts	T098	C0599755
27565913	851	860	discovery	T052	C1880355
27565913	865	875	validation	T062	C1519941
27565913	878	886	analyzed	T062	C0936012
27565913	922	942	molecular components	T123	C0574031
27565913	946	951	serum	T031	C0229671
27565913	978	988	endogenous	T169	C0205227
27565913	989	998	peptidome	T116	C0030956
27565913	1000	1014	discriminating	T080	C0205235
27565913	1015	1023	patients	T101	C0030705
27565913	1029	1034	early	T079	C2363430
27565913	1035	1046	lung cancer	T191	C0242379
27565913	1082	1091	discovery	T052	C1880355
27565913	1092	1098	cohort	T098	C0599755
27565913	1135	1141	cancer	T191	C0006826
27565913	1142	1152	classifier	T169	C4291659
27565913	1158	1163	model	T170	C3161035
27565913	1182	1207	negative predictive value	T081	C1513918
27565913	1217	1237	area under the curve	T081	C0376690
27565913	1239	1242	AUC	T081	C0376690
27565913	1255	1280	negative predictive value	T081	C1513918
27565913	1296	1321	positive predictive value	T081	C1514243
27565913	1343	1353	classifier	T169	C4291659
27565913	1386	1392	cohort	T098	C0599755
27565913	1415	1426	sample sets	T031	C0178913
27565913	1428	1431	AUC	T081	C0376690
27565913	1438	1441	NPV	T081	C1513918
27565913	1450	1453	PPV	T081	C1514243
27565913	1475	1493	serum mass profile	T059	C1446041
27565913	1501	1510	signature	T169	C1704864
27565913	1523	1531	patients	T101	C0030705
27565913	1537	1542	early	T079	C2363430
27565913	1543	1554	lung cancer	T191	C0242379
27565913	1570	1576	marker	T201	C0005516
27565913	1581	1599	insufficient value	T080	C0231180
27565913	1605	1634	stand-alone preselecting tool	T062	C0242481
27565913	1639	1644	LD-CT	T060	C0040405
27565913	1645	1654	screening	T058	C0220908
27565913	1693	1703	evaluation	T058	C0220825
27565913	1707	1720	indeterminate	T078	C0205258
27565913	1721	1738	pulmonary nodules	T033	C0034079
27565913	1756	1769	investigation	T058	C0220825